ALT5 Sigma (NASDAQ:ALTS) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• ALT5 Sigma (NASDAQ:ALTS) has received a "Sell (D-)" rating from Weiss Ratings, indicating continued negative sentiment from analysts.
• In a separate report, Wall Street Zen downgraded the company's rating from "hold" to "strong sell," contributing to an overall average rating of "Sell."
• Shares currently trade at $2.79, with a 52-week range between $1.65 and $10.95, reflecting a significant drop from its previous highs.

ALT5 Sigma (NASDAQ:ALTS - Get Free Report)'s stock had its "sell (d-)" rating reissued by stock analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen lowered ALT5 Sigma from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of "Sell".

ALT5 Sigma Stock Performance

Shares of ALT5 Sigma stock traded up $0.01 during trading hours on Wednesday, reaching $2.79. 6,010,623 shares of the company's stock were exchanged, compared to its average volume of 3,221,745. ALT5 Sigma has a 52-week low of $1.65 and a 52-week high of $10.95. The company has a fifty day moving average of $5.15 and a 200-day moving average of $6.30. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 1.45.

Hedge Funds Weigh In On ALT5 Sigma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in shares of ALT5 Sigma during the second quarter valued at about $380,000. Geode Capital Management LLC grew its stake in shares of ALT5 Sigma by 27.6% during the second quarter. Geode Capital Management LLC now owns 194,813 shares of the company's stock valued at $1,412,000 after acquiring an additional 42,157 shares in the last quarter. Evernest Financial Advisors LLC acquired a new stake in shares of ALT5 Sigma during the second quarter valued at about $87,000. Finally, Bridgeway Capital Management LLC grew its stake in shares of ALT5 Sigma by 9.4% during the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company's stock valued at $140,000 after acquiring an additional 1,661 shares in the last quarter. Hedge funds and other institutional investors own 6.27% of the company's stock.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.